AstraZeneca India Gets Approval To Market Drug Treating Breast Cancer DGCI

DGCI Give Approval For Breast Cancer Medicine: Breast cancer is...

DGCI Give Approval For Breast Cancer Medicine: Breast cancer is a big problem for women. Due to its late detection, the death rate in the country is increasing. At the same time, now breast cancer can be treated in time. Also the medicine is easily available. Because pharmaceutical company AstraZeneca India said on Friday (August 18), has got approval from the Drug Controller General of India for marketing its drug for the treatment of breast cancer. The Drug Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early-stage breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.

AstraZeneca India said in a statement, “This approval was based on the results of the Olympia phase trial, which suggested Olaparib significantly improved the overall figure.” With DCGI approval for the treatment of early stage breast cancer, Lynparza is now approved in the US, European Union, Japan, India and several other countries.

First drug to treat breast cancer gene
In fact, it is currently the first and only approved drug to treat BRCA (breast cancer gene) in early stage breast cancer. Gagandeep Singh, Managing Director, AstraZeneca India said, “The regulatory approval of Linparza… strengthens our growing capabilities in protocol and research to provide holistic solutions for cancer treatment in India.”

cancer patients
Gagandeep Singh said, Breast cancer is one of the most commonly diagnosed cancers worldwide, with an estimated 23 lakh patients being treated every year. Non-communicable diseases (NCDs) such as cancer account for 62 per cent of all deaths and 48 per cent of premature deaths in India today. “Our oncology portfolio has been steadily growing in the range of 40 to 50 per cent in the last three years,” he said.

Spin on News

Spin On News Provide Best Content .

Leave Your Comment